Eutilex said that it has agreed with Microuni to jointly research a next-generation mRNA expression system to develop an infectious disease and anticancer vaccine. Microuni is a bio venture established by a research team at Chungbuk National University Medical School.

Eutliex and Microuni will conduct joint research on a next-generation mRNA expression system to develop infectious diseases or anticancer vaccines.
Eutliex and Microuni will conduct joint research on a next-generation mRNA expression system to develop infectious diseases or anticancer vaccines.

The two companies plan to utilize Microuni’s mRNA vector and lipid nanoparticles (LNP) platform technology for neo-Ag expression, a new antigen, confirmed through Eutilex's next-generation sequencing (NGS) method.

According to Eutilex, the platform technology allows mass-production of mRNA and induces concentrated expression of immune organs in the body.

“Using Microuni’s mRNA and LNP platform technology, the two companies can cooperate in developing infectious disease vaccines and anticancer vaccines,” Microuni CEO Song Min-seok said. “We have high expectations for the joint research."

Eutilex CEO Choi Soo-young also said, "Eutilex will make ceaseless efforts to conquer human cancer through research and development ranging from immunotherapies to anticancer vaccines."

Copyright © KBR Unauthorized reproduction, redistribution prohibited